111 related articles for article (PubMed ID: 10413641)
1. Minimal myocardial damage during coronary intervention is associated with impaired outcome.
Simoons ML; van den Brand M; Lincoff M; Harrington R; van der Wieken R; Vahanian A; Rutsch W; Kootstra J; Boersma E; Califf RM; Topol E
Eur Heart J; 1999 Aug; 20(15):1112-9. PubMed ID: 10413641
[TBL] [Abstract][Full Text] [Related]
2. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.
Hamm CW; Heeschen C; Goldmann B; Vahanian A; Adgey J; Miguel CM; Rutsch W; Berger J; Kootstra J; Simoons ML
N Engl J Med; 1999 May; 340(21):1623-9. PubMed ID: 10341274
[TBL] [Abstract][Full Text] [Related]
3. Prehospital versus periprocedural abciximab in ST-elevation myocardial infarction treated by percutaneous coronary intervention.
Pels K; Schröder J; Witzenbichler B; Müller D; Morguet A; Pauschinger M; Schultheiss HP; Arntz HR
Eur J Emerg Med; 2008 Dec; 15(6):324-9. PubMed ID: 19078834
[TBL] [Abstract][Full Text] [Related]
4. The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications.
Narins CR; Miller DP; Califf RM; Topol EJ
J Am Coll Cardiol; 1999 Mar; 33(3):647-53. PubMed ID: 10080464
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes following "rescue" administration of abciximab in patients undergoing percutaneous coronary angioplasty.
Fuchs S; Kornowski R; Mehran R; Gruberg L; Satler LF; Pichard AD; Kent KM; Stone GW; Leon MB
J Invasive Cardiol; 2000 Oct; 12(10):497-501. PubMed ID: 11022207
[TBL] [Abstract][Full Text] [Related]
6. Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial).
Nikolsky E; Grines CL; Cox DA; Garcia E; Tcheng JE; Sadeghi M; Mehran R; Lansky AJ; Na Y; Stone GW
Am J Cardiol; 2007 Apr; 99(8):1055-61. PubMed ID: 17437727
[TBL] [Abstract][Full Text] [Related]
7. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up.
Montalescot G; Antoniucci D; Kastrati A; Neumann FJ; Borentain M; Migliorini A; Boutron C; Collet JP; Vicaut E
Eur Heart J; 2007 Feb; 28(4):443-9. PubMed ID: 17251257
[TBL] [Abstract][Full Text] [Related]
8. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study.
Campo G; Valgimigli M; Gemmati D; Percoco G; Tognazzo S; Cicchitelli G; Catozzi L; Malagutti P; Anselmi M; Vassanelli C; Scapoli G; Ferrari R
J Am Coll Cardiol; 2006 Dec; 48(11):2178-85. PubMed ID: 17161242
[TBL] [Abstract][Full Text] [Related]
9. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Guagliumi G; Stone GW; Cox DA; Stuckey T; Tcheng JE; Turco M; Musumeci G; Griffin JJ; Lansky AJ; Mehran R; Grines CL; Garcia E
Circulation; 2004 Sep; 110(12):1598-604. PubMed ID: 15353506
[TBL] [Abstract][Full Text] [Related]
10. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials.
Kandzari DE; Hasselblad V; Tcheng JE; Stone GW; Califf RM; Kastrati A; Neumann FJ; Brener SJ; Montalescot G; Kong DF; Harrington RA
Am Heart J; 2004 Mar; 147(3):457-62. PubMed ID: 14999194
[TBL] [Abstract][Full Text] [Related]
11. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW;
Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213
[TBL] [Abstract][Full Text] [Related]
12. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention.
Bellandi F; Maioli M; Gallopin M; Toso A; Dabizzi RP
Catheter Cardiovasc Interv; 2004 Jun; 62(2):186-92. PubMed ID: 15170708
[TBL] [Abstract][Full Text] [Related]
13. Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy.
Bertrand OF; Rodés-Cabau J; Rinfret S; Larose E; Bagur R; Proulx G; Gleeton O; Costerousse O; De Larochellière R; Roy L
Am J Cardiol; 2009 Nov; 104(9):1235-40. PubMed ID: 19840568
[TBL] [Abstract][Full Text] [Related]
14. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.
Stone GW; Grines CL; Cox DA; Garcia E; Tcheng JE; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Carroll JD; Rutherford BD; Lansky AJ;
N Engl J Med; 2002 Mar; 346(13):957-66. PubMed ID: 11919304
[TBL] [Abstract][Full Text] [Related]
15. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.
Montalescot G; Barragan P; Wittenberg O; Ecollan P; Elhadad S; Villain P; Boulenc JM; Morice MC; Maillard L; Pansiéri M; Choussat R; Pinton P;
N Engl J Med; 2001 Jun; 344(25):1895-903. PubMed ID: 11419426
[TBL] [Abstract][Full Text] [Related]
16. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
[TBL] [Abstract][Full Text] [Related]
17. Increased creatine kinase MB level predicts postoperative mortality after cardiac surgery independent of new Q waves.
Ramsay J; Shernan S; Fitch J; Finnegan P; Todaro T; Filloon T; Nussmeier NA
J Thorac Cardiovasc Surg; 2005 Feb; 129(2):300-6. PubMed ID: 15678039
[TBL] [Abstract][Full Text] [Related]
18. Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes.
Mahaffey KW; Roe MT; Kilaru R; French JK; Alexander JH; Berdan LG; Van De Werf F; Simoons ML; Weaver WD; White HD; Lincoff AM; Kleiman NS; Topol EJ; Harrington RA
Am J Cardiol; 2005 Jun; 95(12):1404-8. PubMed ID: 15950560
[TBL] [Abstract][Full Text] [Related]
19. Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy.
Gibson CM; Murphy SA; Marble SJ; Cohen DJ; Cohen EA; Lui HK; Young J; Kitt MM; Lorenz TJ; Tcheng JE
Am Heart J; 2002 Jan; 143(1):106-10. PubMed ID: 11773919
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: a meta-analysis of randomized trials.
Navarese EP; Kozinski M; Obonska K; Margheri M; Gurbel PA; Kubica J; De Luca G
Platelets; 2012; 23(4):274-81. PubMed ID: 21988317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
